Search Results
Showing Results for Fatty liver
At touchENDOCRINOLOGY, we’re proud to support Global Fatty Liver Day on 12 June, an important initiative led by the Global Liver Institute. This annual campaign highlights the growing urgency of fatty liver disease, especially in its advanced stages, and calls on both healthcare professionals and the public to take meaningful action through education, early detection and healthy lifestyle choices.
Polycystic ovary syndrome (PCOS) is a complex, multisystemic condition characterized by reproductive, metabolic and dermatologic manifestations, including hyperandrogenism and ovulatory dysfunction. Despite its prevalence and significant impact on quality of life, PCOS remains underdiagnosed and poorly managed due to its ...
Article Highlights This study aims to find an effective and affordable biomarker panel for early non-alcoholic fatty liver disease (NAFLD) detection in Indian women with morbid obesity, given the rising prevalence of NAFLD and limited accessibility of ultrasound sonography (USG) ...
Article highlights There is growing clinical importance attributed to the development of metabolic dysfunction-associated steatotic liver disease in people with type 2 diabetes (T2D). Numerous international groups now advocate screening for advanced fibrosis in people with risk factors, such as ...
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age and is characterized by hyperandrogenism, anovulation and insulin resistance (IR).1 Women with PCOS have a high risk of developing type 2 diabetes (T2D), dyslipidaemia, hypertension and ...
New research presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting, reveals a connection between low levels of anti-Müllerian hormone (AMH) and the risk of metabolic-associated steatotic liver disease (...
New research is shedding light on the evolving landscape of liver transplants (LT) for non-cancer conditions in the United States. Dr Abdellatif Ismail (University of Maryland Medical Center, Midtown Campus, Baltimore, MD, USA) focuses on how underlying liver diseases – and ...
It is with great pleasure that we present this latest issue of touchREVIEWS in Endocrinology, which brings together a diverse array of high-quality articles focused on the evolving landscape of endocrine disorders. The importance of patient-centred care is exemplified in ...
Hepatic steatosis is the liver manifestation of metabolic syndrome and a common cause of chronic liver disease. Nonalcoholic fatty liver disease (NAFLD) diagnosis relies on the presence of hepatic steatosis, defined as >5% fat accumulation in the liver, as observed ...
Dipeptidyl peptidase-4 (DPP-4) is a ubiquitous, multifunctional, 766-amino acid, type 2 transmembrane glycoprotein, which participates in the regulation of metabolic functions, immune and inflammatory responses, cancer growth and cell adhesion.1 It has two forms: the first is a membrane-bound form, which ...
Metformin Metformin has been recommended as the first-line glucose-lowering agent for the management of type 2 diabetes (T2D) for several decades due to its efficacy and safety profile.1–3 In fact, metformin has been widely used as an insulin-sensitizing agent for ...
Tirzepatide is a first-in-class novel dual glucose-dependent insulinotropic peptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist (twincretin), formulated as a synthetic peptide containing 39 amino acids based on the native GIP.1 Tirzepatide has a GIP receptor-binding affinity comparable with native GIP and ...
Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a range of review, case report and original research articles that highlight some key developments in our understanding and management of endocrinological disease. We begin with a commentary from ...
Type 2 diabetes (T2D) continues to pose an ever-greater global health challenge, with 1.31 billion individuals predicted to be living with diabetes globally by 2050; the majority of whom will have T2D.1 Closely linked to T2D is metabolic dysfunction-associated steatotic ...
Gestational diabetes mellitus (GDM) is generally defined as “any degree of glucose tolerance with onset or first recognition during pregnancy”.1 It currently is one of the diseases with the highest morbidity among pregnant women.2 Determining its prevalence has been a ...
There has been an exponential increase in the global prevalence of obesity over the past few decades because of adverse lifestyle choices, such as physical inactivity and overconsumption of macronutrients. The obesity pandemic has contributed to more than 50 different disorders ...
Diabetes mellitus (DM) is a group of metabolic disorders marked by elevated blood glucose. It has many subtypes, including type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes and neonatal diabetes; of these, T1DM and T2...
Liver conditions are often misunderstood, mischaracterized and stigmatized, which results in under-diagnosis, under-treatment and unnecessarily poor outcomes worldwide. The Global Liver Institute (GLI) "Liver Health is Public Health" initiative aims to respond to this unmet need and educate the public ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
